Natriumoxybat Accord (Sodium Oxybate)

Sodium Oxybate, the active ingredient in Natriumoxybat Accord, is a gamma‑hydroxybutyrate (GHB) CNS depressant presented as an oral formulation for oral use. It is indicated for the treatment of narcolepsy, specifically addressing cataplexy and excessive daytime sleepiness in affected patients.

GNH USA supplies Natriumoxybat Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sodium Oxybate is used in the management of narcolepsy and its related symptom complex. - Narcolepsy with cataplexy: reduces the frequency and severity of cataplexy episodes. - Excessive daytime sleepiness (narcolepsy): improves wakefulness and reduces daytime sleepiness. - Nighttime sleep quality (narcolepsy): enhances slow‑wave sleep, leading to more restorative sleep.

Sodium Oxybate may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Dizziness: sensation of light‑headedness. - Nasal congestion: blockage or runny nose.

Serious or Rare Side Effects: - Respiratory depression: reduced breathing effort, potentially life‑threatening. - Seizures: occurrence of convulsive episodes. - Severe hypotension: marked drop in blood pressure causing faintness.

When prescribing Sodium Oxybate, clinicians should observe several safety precautions. - Contraindication: avoid use in patients with known hypersensitivity to sodium oxybate or GHB. - Respiratory risk: monitor patients with compromised breathing or sleep‑disordered breathing. - Alcohol interaction: advise patients to abstain from alcohol while on therapy. - Pregnancy and lactation: use only if potential benefit justifies potential risk; discuss with obstetrician. - Store at ambient temperature: keep below 25 °C in the original container, protected from moisture and light.

Sodium Oxybate can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Central nervous system depressants (e.g., benzodiazepines, opioids): additive sedation and respiratory depression. - Sodium‑containing medications (e.g., high‑dose sodium bicarbonate): risk of sodium overload and hypertension.

Moderate Interactions (Monitor Closely): - Antidepressants (especially SSRIs): may increase risk of serotonin syndrome. - Antihypertensive agents: potential enhancement of blood‑pressure‑lowering effect. - Anticonvulsants: possible alteration of seizure threshold.